Another study showed that simultaneously targeting cMYC and P53 modulation can cure chronic myeloid leukemia, where cMYC inhibition, coupled with P53 stabilization, targets leukemic stem cells for elimination [24]. Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.